HeartSciences (HSCS) Net Cash Flow (2021 - 2026)

HeartSciences (HSCS) has reported Net Cash Flow for 6 consecutive years, with -$1.7 million the latest figure, recorded in Q2 2026.

• Quarterly Net Cash Flow fell 16.14% year-over-year to -$1.7 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was -$887216.0 (up 81.16% YoY) and the FY2026 annual result came in at $558716.0, up 111.86% from the prior year.
• Net Cash Flow eased to -$1.7 million in Q2 2026 per HSCS's latest filing, from -$841128.0 in the prior quarter.
• Over the last five years, Net Cash Flow for HSCS reached as high as $7.0 million in Q1 2024 and fell as low as -$1.7 million in Q2 2026.
• A 5-year average of -$9382.2 and a median of -$841128.0 in 2025 frame the typical range for Net Cash Flow.
• The largest YoY upside for Net Cash Flow was 709.28% in 2024 against a maximum downside of 369.1% in 2024.
• Year by year, Net Cash Flow stood at -$1.2 million in 2022, then soared by 60.26% to -$475510.0 in 2023, then jumped by 39.51% to -$287658.0 in 2024, then slumped by 192.41% to -$841128.0 in 2025, then tumbled by 106.89% to -$1.7 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$1.7 million, -$841128.0, and $1.7 million for Q2 2026, Q4 2025, and Q3 2025 respectively.